Delving into the Latest Updates on SL-145 with Synapse

Author: Park, Minsu ; Kim, Yoon-Jae ; Park, Soeun ; Ann, Jihyae ; Seo, Jae Hong ; Kim, Ji Young ; Cho, Tae-Min ; Thanh La, Minh ; Kim, Seongjae ; Park, Jung Min ; Hoang, Van-Hai ; Seo, Juyeon ; Jung, Eunsun ; Nam, Gibeom ; Farrand, Lee ; Park, Hyun-Ju ; Ko, Dongmi ; Nam, Kee Dal ; Lee, Jeewoo ; Nguyen, Cong-Truong

AbstractDespite recent advances, there remains a significant unmet need for the development of new targeted therapies for triple-negative breast cancer (TNBC). Although the heat shock protein HSP90 is a promising target, previous inhibitors have had issues during development including undesirable induction of the heat shock response (HSR) and off-target effects leading to toxicity. SL-145 is a novel, rationally-designed C-terminal HSP90 inhibitor that induces apoptosis in TNBC cells via the suppression of oncogenic AKT, MEK/ERK, and JAK2/STAT3 signaling and does not trigger the HSR, in contrast to other inhibitors. In an orthotopic allograft model incorporating breast cancer stem cell-enriched TNBC tumors, SL-145 potently suppressed tumor growth, angiogenesis, and metastases concomitant with dysregulation of the JAK2/STAT3 signaling pathway. Our findings highlight the potential of SL-145 in suppressing metastatic TNBC independent of the HSR.

100 Deals associated with SL-145

Login to view more data